Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: Vein-to-Vein Time as a Clinical Variable
DOI:
https://doi.org/10.5281/zenodo.22649019Keywords:
Chimeric Antigen Receptor T-Cell Manufacturing Turnaround;, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Chimeric Antigen Receptor T-Cell Manufacturing Turnaround is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for chimeric antigen
receptor t-cell manufacturing turnaround, spanning analytical, clinical, implementation, governance, and economic dimensions,
focusing on where practice has converged and where it continues to vary, and set out the practical considerations relevant to a
service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently
available, rather than uniform adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/48297
Brankovic K, Kowalczyk B, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1007/s00330-025-12031-z
Castellani R, Ristic C, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3389/fdgth.2026.1699005
Dumitrescu A, Andric D, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1834800
Eriksdottir B, Brankovic E, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.2196/69678
Farkas I, Ionescu F, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.7759/cureus.46454
Grabowski P, Petrescu G, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1016/j.ssci.2025.107028
Hendriksen W, Wojcik H, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/48633
Ionescu F, Foscarini I, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1371/journal.pone.0305949
Jankowiak G, Grabowski J, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pdig.0000514
Kowalczyk N, Novotna K, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.17219/acem/208596
Lindqvist U, Urbanek L, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.7759/cureus.104086
Marchetti D, Doncheva M, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1038/s41746-023-00852-5
Novotna E, Eriksdottir N, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1016/j.mayocpiqo.2022.09.004
Ostrowski L, Lindqvist O, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1177/08404704241291226
Petrescu S, Szabo P, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1093/medlaw/fwad013
Quintero B, Balogh Q, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.2196/89834
Ristic C, Castellani R, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1007/s10916-024-02104-9
Szabo J, Jankowiak S, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.3389/fdgth.2026.1896184
Tarasov Q, Quintero T, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3390/diagnostics15162117
Urbanek Z, Zielinski U, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.4103/jrpp.jrpp_20_65
Vasquez A, Alvez V, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.3389/fdgth.2026.1763884
Wojcik H, Hendriksen W, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/48297
Zielinski O, Ostrowski Z, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1007/s00330-025-12031-z
Andric V, Vasquez A, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3389/fdgth.2026.1699005
Balogh E, Emmerich B, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1834800
Chiriac F, Farkas C, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.2196/69678
Doncheva M, Marchetti D, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a validation study". Trials 22(2017): 377-383. DOI: 10.7759/cureus.46454
Emmerich T, Tarasov E, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1016/j.ssci.2025.107028
Foscarini C, Chiriac F, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/48633
Alvez D, Dumitrescu A, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1371/journal.pone.0305949
Brankovic K, Kowalczyk B, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pdig.0000514
Castellani R, Ristic C, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.17219/acem/208596
Dumitrescu A, Andric D, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.7759/cureus.104086
Eriksdottir B, Brankovic E, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1038/s41746-023-00852-5
Farkas I, Ionescu F, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1016/j.mayocpiqo.2022.09.004
Grabowski P, Petrescu G, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1177/08404704241291226
Hendriksen W, Wojcik H, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1093/medlaw/fwad013
Ionescu F, Foscarini I, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a scoping review". JAMA 44(2020): 498-506. DOI: 10.2196/89834
Jankowiak G, Grabowski J, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1007/s10916-024-02104-9
Kowalczyk N, Novotna K, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.3389/fdgth.2026.1896184
Lindqvist U, Urbanek L, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3390/diagnostics15162117
Marchetti D, Doncheva M, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.4103/jrpp.jrpp_20_65
Novotna E, Eriksdottir N, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.3389/fdgth.2026.1763884
Ostrowski L, Lindqvist O, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/48297
Petrescu S, Szabo P, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1007/s00330-025-12031-z
Quintero B, Balogh Q, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3389/fdgth.2026.1699005
Ristic C, Castellani R, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1834800
Szabo J, Jankowiak S, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.2196/69678
Tarasov Q, Quintero T, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.7759/cureus.46454
Urbanek Z, Zielinski U, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1016/j.ssci.2025.107028
Vasquez A, Alvez V, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/48633
Wojcik H, Hendriksen W, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1371/journal.pone.0305949
Zielinski O, Ostrowski Z, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pdig.0000514
Andric V, Vasquez A, et al. "Chimeric Antigen Receptor T-Cell Manufacturing Turnaround: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.17219/acem/208596
